Is Amkay Products overvalued or undervalued?

As of 15 September 2025, the valuation grade for Amkay Products has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 13.61, an EV to EBITDA of 11.27, and a ROE of 13.88%.
In comparison to its peers, Amkay Products stands out with a much lower PE ratio than Poly Medicure (56.25) and Blue Jet Health (34.63), both categorized as very expensive. This suggests that Amkay Products offers a more favorable valuation relative to its competitors. Despite a recent decline in stock performance compared to the Sensex, where it has underperformed with a year-to-date return of -15.87% against the Sensex's 4.67%, the underlying financial metrics indicate that the company is positioned well for potential growth.